

Supplementary Table 1 Primer Information for qRT-PCR Analysis of miRNAs

miRNAs	Sequence name	Sequence (5' UTR-3' UTR)
miR-22-5p	F	CGCGAGTTCCTTCAGTGGCAA
	R	AGTGCAGGGTCCGAGGTATT
	RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCCG CACTGGATACGACTAAAGC
miR-10a-5p	F	CGCGTACCCTGTAGATCCGAA
	R	AGTGCAGGGTCCGAGGTATT
	RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCCG CACTGGATACGACCACAAA
miR-126-3p	F	CGCGTCGTACCGTGAGTAAT
	R	AGTGCAGGGTCCGAGGTATT
	RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCCG CACTGGATACGACCGCATT
miR-7706	F	TGAAGCGCCTGTGCTCTG
	R	AGTGCAGGGTCCGAGGTATT
	RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCCG CACTGGATACGACTCTCGG
miR-223-3p	F	GCGCGTGTCAGTTTGTCAAAT
	R	AGTGCAGGGTCCGAGGTATT
	RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCCG CACTGGATACGACTGGGGT
miR-556-5p	F	CGCGGATGAGCTCATTGTAA
	R	AGTGCAGGGTCCGAGGTATT
	RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCCG CACTGGATACGACCTCATA
miR-130a-3p	F	CGCGCAGTGCAATGTTAAAA
	R	AGTGCAGGGTCCGAGGTATT

miR-219-5p	RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCG CACTGGATACGACATGCCC
	F	CGTGATTGTCCAAACGCAA
	R	AGTGCAGGGTCCGAGGTATT
miR-3909	RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCG CACTGGATACGACCGAGAA
	F	GCGTGTCTCTAGGGCCTG
	R	AGTGCAGGGTCCGAGGTATT
miR-146b-3p	RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCG CACTGGATACGACAGACTG
	F	CGGCCCTGTGGACTCAGT
	R	AGTGCAGGGTCCGAGGTATT
miR-6513-3p	RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCG CACTGGATACGACACCAGA
	F	GCGCGTCAAGTGTCTCTGTC
	R	AGTGCAGGGTCCGAGGTATT
U6	RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCG CACTGGATACGACCCTAGG
	F	CTCGCTTCGGCAGCACA
	R	AACGCTTCACGAATTTGCGT

Supplementary Table 2 Biochemical characteristics of test cohort patients

	DR (<i>n</i> = 13)	DS (<i>n</i> = 17)	<i>t</i> / <i>Z</i>	<i>P</i> value
Sex (female/male)	13/0	15/2	/	0.492
Age (year)	54.92 ± 10.21	49.18 ± 8.72	1.662	0.108
ALT (pre-treatment), U/L	37.00 (19.50, 74.50)	28.00 (23.50, 50.50)	0.44	0.672
ALT (post-treatment), U/L	43.00 (19.50, 62.50)	31.00 (22.00, 42.50)	0.921	0.368
AST (pre-treatment), U/L	85.00 (37.00, 118.50)	43.00 (35.50, 69.00)	1.549	0.125
AST (post-treatment), U/L	58.00 (36.50, 93.50)	41.00 (28.00, 47.50)	2.261	0.023
ALP (pre-treatment), U/L	230.00 (112.50, 398.50)	206.00 (175.00, 287.00)	0.293	0.781
ALP (post-treatment), U/L	186.00 (115.00, 478.00)	159.00 (132.00, 246.00)	0.502	0.628
GGT (pre-treatment), U/L	112.00 (53.00, 452.00)	212.00 (112.50, 271.50)	0.398	0.711
GGT (post-treatment), U/L	117.00 (23.00, 196.50)	69.00 (47.00, 161.50)	0.272	0.797
TBIL (pre-treatment), umol/L	25.50 (18.20, 46.95)	13.00 (8.25, 21.45)	2.972	0.002
TBIL (post-treatment), umol/L	25.60 (20.20, 50.70)	11.50 (7.85, 15.10)	4.583	< 0.001
LDH (pre-treatment), U/L	188.00 (140.50, 230.00)	163.00 (151.00, 206.50)	0.523	0.621
LDH (post-treatment), U/L	178.00 (145.50, 269.50)	166.00 (143.00, 201.50)	0.691	0.502
IgG (pre-treatment), U/L	16.62 (14.06, 18.74)	13.43 (11.43, 15.77)	2.281	0.022
IgG (post-treatment), U/L	14.34 (12.55, 18.18)	13.24 (11.99, 15.52)	1.109	0.276
IgA (pre-treatment), U/L	2.32 (1.52, 3.34)	2.11 (1.35, 2.32)	1.507	0.136
IgA (post-treatment), U/L	2.60 (1.26, 3.95)	2.02 (1.41, 2.51)	1.465	0.148
IgM (pre-treatment), U/L	2.38 (1.49, 5.39)	2.80 (2.13, 3.79)	0.523	0.621
IgM (post-treatment), U/L	2.70 (1.30, 4.66)	2.20 (1.77, 3.04)	0.063	0.959
AMA (+/-)	9/4	11/6	/	1.000
Gp210 (+/-)	8/5	13/4	/	0.443
Sp100 (+/-)	0/13	4/13	/	0.113

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: Glutamyltranspeptidase; TBIL: Total bilirubin;

LDH: Lactate dehydrogenase; IgG: Immunoglobulin G; IgA: Immunoglobulin A; IgM: Immunoglobulin M; AMA: Anti-mitochondrial antibody.